AIGH Capital Management LLC Cuts Stake in Personalis, Inc. (NASDAQ:PSNL)

AIGH Capital Management LLC reduced its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,799,064 shares of the company's stock after selling 200,000 shares during the quarter. Personalis makes up 6.9% of AIGH Capital Management LLC's portfolio, making the stock its 3rd largest holding. AIGH Capital Management LLC owned approximately 5.38% of Personalis worth $21,959,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. abrdn plc acquired a new position in Personalis in the fourth quarter valued at about $1,722,000. Walleye Capital LLC bought a new position in shares of Personalis in the third quarter valued at approximately $897,000. Jane Street Group LLC boosted its holdings in shares of Personalis by 154.3% in the 3rd quarter. Jane Street Group LLC now owns 164,281 shares of the company's stock worth $884,000 after acquiring an additional 99,671 shares in the last quarter. Geode Capital Management LLC grew its position in Personalis by 20.0% during the 3rd quarter. Geode Capital Management LLC now owns 498,470 shares of the company's stock worth $2,683,000 after acquiring an additional 83,068 shares during the last quarter. Finally, Centiva Capital LP acquired a new stake in Personalis during the 3rd quarter valued at $380,000. Institutional investors own 61.91% of the company's stock.

Analyst Upgrades and Downgrades

PSNL has been the subject of a number of research reports. Needham & Company LLC lowered their target price on Personalis from $7.25 to $7.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Lake Street Capital upped their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Craig Hallum assumed coverage on shares of Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Personalis in a report on Friday, February 28th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $7.80.

Remove Ads

Personalis Stock Down 7.0 %

Shares of Personalis stock traded down $0.25 during trading on Thursday, reaching $3.31. 331,987 shares of the company were exchanged, compared to its average volume of 938,701. The firm has a market capitalization of $292.15 million, a price-to-earnings ratio of -1.97 and a beta of 1.89. The business has a 50-day moving average price of $4.49 and a 200-day moving average price of $4.74. Personalis, Inc. has a twelve month low of $1.14 and a twelve month high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.09. The firm had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. On average, equities research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.